Table 2 Distributions of clinico-pathological variables between non-progression and progression groups among training and testing cohorts
From: Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer
Variable | Training (N = 267) | Testing (N = 115) | ||||
|---|---|---|---|---|---|---|
Non-BCR | BCR | P value | Non-BCR | BCR | P value | |
N | 217 | 50 | Â | 93 | 22 | Â |
Age at RP (years) | 58.1 (8.3) | 59.2 (8.3) | Â | 57.3 (8.4) | 59.9 (8.6) | Â |
 Mean (SD) | 58.8 (40.7–76.1) | 61.2 (42.6–70.6) | 0.271 | 57.5 (40.6–76.9) | 62.1 (41.4–70.7) | 0.081 |
Race—N (%) | ||||||
 CA & Other | 179 (82.5) | 38 (17.5) |  | 79 (81.4) | 18 (18.6) |  |
 AA | 38 (76.0) | 12 (24.0) |  | 14 (77.8) | 4 (22.2) |  |
Pathological T stage—N (%) | ||||||
 pT2 | 164 (89.6) | 19 (10.4) |  | 68 (89.5) | 8 (10.5) |  |
 pT3–4 | 43 (62.3) | 26 (37.7) | < 0.001 | 19 (67.9) | 9 (32.1) | 0.008 |
Gleason sum—N (%) | ||||||
 3 + 3 | 24 (90.8) | 12 (9.2) |  | 60 (90.9) | 6 (9.1) |  |
 3 + 4 | 65 (89.0) | 8 (11.0) |  | 26 (81.2) | 6 (18.8) |  |
 4 + 3/8 − 10 | 24 (53.3) | 21 (46.7) | < 0.001 | 7 (46.7) | 8 (53.3) | < 0.001 |
Surgical margin—N (%) | ||||||
 Negative | 189 (84.8) | 34 (15.2) |  | 74 (84.1) | 14 (15.9) |  |
 Positive | 27 (64.3) | 15 (35.7) | 0.001 | 19 (70.4) | 8 (29.6) | 0.114 |